Experience in Borderline Ovarian Tumors

Borderline Ovarian Tumors: Results of a Retrospective, Single-center Experience

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05791838

Enrollment

Registered

2023-03-30

Start date

2023-03-31

Completion date

2023-03-31

Last updated

2023-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Ovarian Tumor

Keywords

Conservative surgery, Micropapillary patterns, Surgical staging

Brief summary

Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers. The present study aimed to report the 8-year experience of a single center on the management and outcomes of consecutive BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical treatment were included. Demographic, clinical, and pathological data were reviewed retrospectively.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years, * Patients affected by borderline ovarian tumors (BOT) of any histological type and any FIGO stage, * Women undergoing surgical treatment with both laparoscopic and laparotomic approaches.

Exclusion criteria

\- Women affected by ovarian cancers

Design outcomes

Primary

Measure	Time frame	Description
Oncological outcome	through study completion, an average of 1 year	Patients who underwent surgery for BOT

Contacts

Primary ContactAndrea Etrusco, M.D.

etruscoandrea@gmail.com+393881715032

Outcome results